{"id":"W2977936382","doi":"10.1093/annonc/mdz394.007","title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Hormone receptor; Cancer; Breast cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292019,0.000891232,0.00118227,0.000211892,0.0002550662,0.0006800636,0.0004293124,0.0005498169,0.002896647],"category_scores_gemma":[0.0006270264,0.0001821313,0.00155687,0.0002787962,0.0004128221,0.0005062905,0.0003301493,0.001675664,0.0004417174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005270608,"about_ca_system_score_gemma":0.0005505943,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006969516,"about_ca_topic_score_gemma":0.002931322,"domain_scores_codex":[0.9997903,0.000102207,0.00001039377,0.00003290261,0.00001713651,0.00004714528],"domain_scores_gemma":[0.9996829,0.00006867416,0.00007291243,0.00002724081,0.00001602839,0.000132262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8537278,0.006768133,0.01670952,0.0008872623,0.004263321,0.0001402467,0.0001359005,0.004657442,0.01486462,0.0003689702,0.009513599,0.08796317],"study_design_scores_gemma":[0.4916834,0.3320801,0.1434157,0.0001616695,0.007117562,0.0005921943,0.0001980169,0.003811872,0.003965444,0.001397475,0.01550133,0.00007516841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851379,0.005286073,0.0002803812,0.0006061642,0.0001779895,0.0003190854,0.003750919,0.0000691247,0.004372335],"genre_scores_gemma":[0.9840174,0.002478146,0.0003949048,0.0009075049,0.0001863899,0.0004550468,0.007709973,0.00002883956,0.003821817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002896647,"threshold_uncertainty_score":0.009690225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02761816145389646,"score_gpt":0.3378950834321779,"score_spread":0.3102769219782814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}